Compare · ABSI vs MEDP
ABSI vs MEDP
Side-by-side comparison of Absci Corporation (ABSI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $12.97B, about 13.0x ABSI ($997.8M).
- Over the past year, ABSI is up 119.9% and MEDP is up 53.5% - ABSI leads by 66.4 points.
- MEDP has been more active in the news (10 items in the past 4 weeks vs 5 for ABSI).
- MEDP has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Medpace Holdings Inc.
- Price
- $6.50+1.96%
- $457.50+0.69%
- Market cap
- $997.8M
- $12.97B
- 1M return
- +13.02%
- +6.61%
- 1Y return
- +119.93%
- +53.50%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 5
- 10
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ABSI
- Absci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Leerink Partners initiated coverage on Absci Corporation with a new price target
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,319 shares, decreasing direct ownership by 2% to 491,464 units (SEC Form 4) to satisfy withholding tax
- BTIG Research initiated coverage on Absci Corporation with a new price target
- Absci to Participate in Upcoming Investor Conferences
- Director Pangalos Menelas N bought $200,748 worth of shares (37,453 units at $5.36), increasing direct ownership by 19% to 232,308 units (SEC Form 4)
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
- Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Latest MEDP
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
- SEC Form 4 filed by Director Zander Dani S.
- SEC Form 4 filed by Director Mccarthy Cornelius P. Iii
- SEC Form 4 filed by Director Kraft Robert O.
- SEC Form 4 filed by Director Gwadry-Sridhar Femida H.
- SEC Form 4 filed by Director Davenport Fred B Jr
- SEC Form 4 filed by Director Carley Brian T